AMHRII expression and Antibody-Drug Conjugate preclinical data suggest potential broader applications for anti-AMHRII-based therapy
This designation has been awarded for the treatment of AMHR2-expressing ovarian cancers, exclusive of AMHR2-expressing fallopian tube cancers and primary peritoneal cancers
Oncotarget journal published an article on GamaMabs’12G4 antibody (3C23K precursor).
Pauline Estupina, Alexandre Fontayne, Jean-Marc Barret, Nathalie Kersual, Olivier Dubreuil, Marion Le Blay, Alexandre Pichard, Marta Jarlier, Martine Pugnière, Maëva Chauvin, Thierry Chardès, Jean-Pierre Pouget, Emmanuel Deshayes, Alexis Rossignol, Toufik Abache, Christophe de Romeuf, Aurélie Terrier, Lucie Verhaeghe, Christine Gaucher, Jean-François Prost, André Pèlegrin, Isabelle Navarro-Teulon, (2017) The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells, Oncotarget
BioDiscovery 4, a fund managed by Edmond de Rothschild Investment Partners, led the round; the funds raised will finance clinical trials for GM102, a therapeutic antibody targeting gynecological cancers
GamaMabs Pharma will present new results from its collaboration with the Institut Curie at TAT meeting (Paris, March 2-4 2015) with a poster describing 3C23K antibody efficacy in combination with chemotherapy in PDX models.
Clinical trials are scheduled for 2015 to explore the value of the candidate drug 3C23K in relapsing ovarian cancer.
GamaMabs Pharma and Mayo Clinic will collaborate on a study on the efficacy of GamaMabs’ 3C23K antibody in ovarian patient-derived xenografts (PDX) models
mAbs journal published an article on GamaMabs’12G4 antibody (3C23K precursor).
Nathalie Kersual, Véronique Garambois, Thierry Chardès, Jean-Pierre Pouget, Imed Salhi, Caroline Bascoul-Mollevi, Frédéric Bibeau, Muriel Busson, Henri Vié, Béatrice Clémenceau, Christian K Behrens, Pauline Estupina, André Pèlegrin & Isabelle Navarro-Teulon (2014) The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer, mAbs, 6:5, 1314-1326